Effect of Vitamins D3 and K2 in uOc and Insulin Serum Levels in Patients With Diabetes Mellitus
Primary Purpose
Diabetes Mellitus, Type 2, Bone Loss, Insulin Resistance
Status
Completed
Phase
Not Applicable
Locations
Mexico
Study Type
Interventional
Intervention
Supplementation with Vitamin D3 y K2
Sponsored by
About this trial
This is an interventional supportive care trial for Diabetes Mellitus, Type 2 focused on measuring diabetes, osteocalcin, insulin
Eligibility Criteria
Inclusion Criteria:
- Originating and residents of Western Mexico
- Both genres
- Age of 30-75 years
- Diagnosis of DM2 (ADA Criteria) of at least 5 years of evolution
- Sign an informed consent letter.
Exclusion Criteria:
- Use of active drugs for bone mineralization
- Pregnancy
- Lactation
- Creatinine or transaminase more than double the upper limit
- Diet added with calcium or vitamins (D, K).
Sites / Locations
- Julio Iván Aguayo
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
Group 1
Group 2
Group 3
Arm Description
Vitamin D3 1000UI + Placebo (Calcined Magnesia).
Vitamin K2 100 mcg + Placebo (Calcined Magnesia).
Vitamin D3 1000UI + Vitamin K2 100 mcg
Outcomes
Primary Outcome Measures
Non-carboxylated osteocalcin
Serum levels
Insulin
Serum levels
Secondary Outcome Measures
Weight
kg
Height
m
Body mass index
Quetelet index
HOMA Index
Insulin resistance
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04041492
Brief Title
Effect of Vitamins D3 and K2 in uOc and Insulin Serum Levels in Patients With Diabetes Mellitus
Official Title
Effect of Supplementation With Vitamins D3 and K2 in Non-carboxyled Osteocalcine and Insulin Serum Levels in Patients With Diabetes Mellitus Type 2
Study Type
Interventional
2. Study Status
Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
February 14, 2017 (Actual)
Primary Completion Date
February 14, 2018 (Actual)
Study Completion Date
February 14, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Guadalajara
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Introduction: Patients with DM2 have chronic hyperglycemia derived from a decrease in insulin sensitivity, cause of comorbidities such as bone demineralization, decreasing quality of life and increasing mortality. This could be related to changes in the serum levels of carboxylated Osteocalcin and Insulin, together with the deficit the daily consumption of vitamins D3 and K, which is crucial for the process of mineralization of the bone matrix.
Research question: What is the effect of supplementation with Vitamins D3 and K2 on serum levels of Carboxylated Osteocalcin and Insulin in patients with Type 2 Diabetes mellitus?
Hypothesis: Supplementation with Vitamins D3 and K2 modifies the serum levels of Carboxylated Osteocalcin and Insulin in patients with Type 2 Diabetes mellitus.
General Objectives: To assess the effect of supplementation with Vitamins D3 and K2 on serum levels of Carboxylated and Non-Carboxylated Osteocalcin in patients with Type 2 Diabetes mellitus.
Material and Methods: Clinical trial, double blind, randomization, 40 patients with DM2, 35-65 years, supplementation (3 months), clinical and laboratory determinations (uOC and Insulin).
Group 1: Vitamin D3 1000UI + Placebo
Group 2: Vitamin K2 100 mcg + Placebo
Group 3 (Positive Control): Vitamins D3 1000UI + K2 100 mcg
Detailed Description
Type 2 diabetes mellitus is a group of metabolic disorders characterized by chronic hyperglycemia, being one of the main causes of mortality in our country.
There are different comorbidities, including bone demineralization, which involve an imbalance in the process of bone formation and resorption, which entails the risk of decreasing bone mineral density. These processes could be related to the serum levels of Non-carboxylated Osteocalcin and Insulin, said molecule locally modulates the process of bone mineralization.
On the other hand, it is known that the daily consumption of vitamins in a general diet in our population (specifically including vitamins D3 and K), is below the necessary basic requirements, so considering crucial elements for the benefit of Bone matrix mineralization, which is why the present study proposes supplementation with the aforementioned vitamins in patients with Type 2 DM, to avoid a decrease in bone mineral density, increasing the mortality rate of individuals suffering from it.
- The study subjects from the West of the country were invited to participate in the research protocol, where their objective was explained and the signing of the consent was requested under information, where a structured evaluation was subsequently carried out consisting of :
a) Comprehensive clinical evaluation (including general sociodemographic data of a complete medical history).
- Once the previous data was obtained, the randomization of the treatment was carried out, classifying the patients in the following groups:
Group 1 Vitamin D3 1000UI + Placebo (Calcined Magnesia).
Group 2 Vitamin K2 100 mcg + Placebo (Calcined Magnesia).
Group 3 (Positive Control) Vitamins D3 1000UI + K2 100 mcg.
- Blood sample collection through Punzocat, which was placed in a red tube, for subsequent centrifugation at 3500rpm x 15 minutes, performing aliquots of the serum obtained and stored at -80 ° C and thus perform the pertinent quantifications of the molecules to study.
- Quantification of serum levels of non-carboxylated Osteocalcin and Insulin
a) The determinations corresponding to the serum levels of Non-carboxylated Osteocalcin and Insulin were made, both baseline prior to the intervention as well as the final quantification, once the supplementation was finished, by means of the indirect ELISA technique (commercial reagents -Takara were used - for the realization of these determinations), which involved the following process: In a plate the wells were coated with a first antibody, then a wash was performed to remove the excess antibody, after that, the sample in which the antigen was found was added, which was retained in the well after being recognized by the first antibody, a second wash was subsequently made to remove unbound material, then a solution with a second labeled anti-antigen antibody was applied. Thus each antigen molecule was bound to an antibody in the base that kept it fixed and a second antibody for its reaction and labeling. Finally, the plate was introduced into a spectophotometer and the absorbance was measured at a length of 450 nm, for both non-carboxylated Osteocalcin and Insulin.
- The quantification in serum of cholesterol and triglycerides was carried out by using the fully automated random access analyzer equipment for clinical chemistry, model ERBA XL 200.
- The evaluation of the HOMA index was calculated by using the equations HOMA-IR and HOMA-B, for insulin resistance (IR) and Percentage, respectively.
- The daily of adherence to treatment was provided, so that they recorded all those important events that would ensure adequate intake of vitamins, as well as adverse reactions to them, which were evaluated in scheduled appointments, in addition to each The corresponding bottles were delivered consecutively for each of the 3 months of intervention, with the corresponding vitamins for each patient according to their allocation group.
- Finally, in the last visit the results obtained during the whole study were made known to each of the patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2, Bone Loss, Insulin Resistance
Keywords
diabetes, osteocalcin, insulin
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Controlled clinical trial, with randomization simple, double blind.
Masking
ParticipantCare ProviderInvestigator
Masking Description
randomization simple, double blind.
Allocation
Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group 1
Arm Type
Experimental
Arm Description
Vitamin D3 1000UI + Placebo (Calcined Magnesia).
Arm Title
Group 2
Arm Type
Experimental
Arm Description
Vitamin K2 100 mcg + Placebo (Calcined Magnesia).
Arm Title
Group 3
Arm Type
Active Comparator
Arm Description
Vitamin D3 1000UI + Vitamin K2 100 mcg
Intervention Type
Dietary Supplement
Intervention Name(s)
Supplementation with Vitamin D3 y K2
Intervention Description
Supplementation at a dose of 1 capsule every 24 hours x 3 months
Primary Outcome Measure Information:
Title
Non-carboxylated osteocalcin
Description
Serum levels
Time Frame
3 months
Title
Insulin
Description
Serum levels
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Weight
Description
kg
Time Frame
3 months
Title
Height
Description
m
Time Frame
3 months
Title
Body mass index
Description
Quetelet index
Time Frame
3 months
Title
HOMA Index
Description
Insulin resistance
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Originating and residents of Western Mexico
Both genres
Age of 30-75 years
Diagnosis of DM2 (ADA Criteria) of at least 5 years of evolution
Sign an informed consent letter.
Exclusion Criteria:
Use of active drugs for bone mineralization
Pregnancy
Lactation
Creatinine or transaminase more than double the upper limit
Diet added with calcium or vitamins (D, K).
Facility Information:
Facility Name
Julio Iván Aguayo
City
Guadalajara
State/Province
Jalisco
ZIP/Postal Code
44730
Country
Mexico
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Non-sharable data
Citations:
PubMed Identifier
32831908
Citation
Aguayo-Ruiz JI, Garcia-Cobian TA, Pascoe-Gonzalez S, Sanchez-Enriquez S, Llamas-Covarrubias IM, Garcia-Iglesias T, Lopez-Quintero A, Llamas-Covarrubias MA, Trujillo-Quiroz J, Rivera-Leon EA. Effect of supplementation with vitamins D3 and K2 on undercarboxylated osteocalcin and insulin serum levels in patients with type 2 diabetes mellitus: a randomized, double-blind, clinical trial. Diabetol Metab Syndr. 2020 Aug 18;12:73. doi: 10.1186/s13098-020-00580-w. eCollection 2020.
Results Reference
derived
Learn more about this trial
Effect of Vitamins D3 and K2 in uOc and Insulin Serum Levels in Patients With Diabetes Mellitus
We'll reach out to this number within 24 hrs